|
|
|
 |
|
Welcome to UroToday’s coverage of the 2017 World Congress of Endourology held in Vancouver, Canada from September 12-16th.
This year’s theme is “A bridge to the future of Endourology” with a focus on new technologies and the latest cutting-edge translational research. UroToday will be providing daily coverage of the WCE meeting and look forward to ongoing coverage.
|
|
|
WCE 2017: The Role of Various Novel Inflammatory Biomarkers Following Flexible Ureterorenoscopy, for the Treatment of Kidney Stones
Dr. Stephan Hughes and colleagues examined how flexible ureterorenoscopy affected changes to novel inflammatory markers. He discussed that there was an increase of post-operative complications (e.g. infection) with an increase of using FURS.
|
|
|
WCE 2017: Medically Expulsive Therapy: Fact or Fiction
Dr. Hollingsworth began the debate for medically expulsive therapy for ureteral stones by bringing up a paper written by Pikard et al. (the SUSPEND trial) and debunking it. Looking at the data more closely, he was surprised to find that spontaneous stone passage in the control group was 80%, which seemed really high.
|
|
|
WCE 2017: A Critical Evaluation of Intra-Renal Pressures Based on Ureteral Access Sheath Size and Irrigation Flow Rate for Safe and Effective Robotic Assisted Retrograde Intra-Renal Surgery
Dr. Kemal Sarica, presented data that evaluated the effects of varying Ureteral Access Sheath sizes (10/12F – 12/14F) and changing irrigation flow rates modulated by a custom designed pump system on intra-renal pressure levels during Robotic assisted retrograde intrarenal surgery.
|
|
|
WCE 2017: Ethnicity and Family History Impact Age of Onset and Number of Episodes for Urolithiasis: A Prospective Cohort Study from ReSKU
Kazumi Taguchi presented data to evaluate the association between detailed family history and clinical outcomes of urolithiasis. The purpose of this study was to perform a multivariate analysis of the relationship between detailed FMH and stone outcomes.
|
|
|
WCE 2017: Supracostal Access Tubeless Percutaneous Nephrolithotomy: Minimizing Complications
Dr. Michael Sourial et al. present a retrospective study of 76 renal units from 70 patients who underwent percutaneous nephrolithotomy with supracostal access. Only a 7F ureteral stent and Foley catheter were left postoperatively; nephrostomy tubes were removed at end-expiration. The median age was 62 years.
|
|
|
WCE 2017: Pre-Clinical Assessment of Peri-operative Complications and Effect on Wound and Tissue Healing of sEphB4-HSA Administration Prior to Surgical Intervention
Dr. Sameer Chopra presented data on the novel cancer therapeutic agent sEphB4-HSA, which works by directly inhibiting the EphB4-Ephrin-B2 interaction to block tumor-vessel interaction and tumor vessel maturation. Since the soluble, intravenous (IV) drug is only in Phase II clinical trials, Dr. Chopra explained in his presentation the concern of the potential linkage between the drug and wound healing inhibition due to the agent’s property of vessel maturation regulation.
|
|
|
WCE 2017: Accuracy of Predicting Stone Composition During
Endoscopic Evaluation
Jennifer Robles presented data that assessed the accuracy of endoscopic evaluation for predicting stone composition intra-operatively. As an introduction to her talk, Dr. Robles explained how predicting stone composition post-operatively has helped direct their management of stone disease.
|
|
|
WCE 2017: Arbutin as a novel prevention and therapy for calcium
oxalate nephrolithiasis
Aymon Ali, a MSc presented the use of Arbutin as a novel prevention and therapy technique for calcium oxalate nephrolithiasis. As an introduction to his talk, Mr. Ali explained how through the use of the Drosophila melanogaster, they successfully screened through 360 compounds and discovered this plant based glycoside Arbutin led to a significant decrease in calculi present in the flies.
|
|
|
WCE 2017: Should All UTUC Patients be Screened for Lynch Syndrome?
A Single Center Analysis of the Role of Screening UTUC patients for
Lynch Syndrome
Matin et al. present a retrospective single-institution study of 115 patients who were diagnosed with upper tract urothelial carcinoma and received point-of-care screening tests for Lynch Syndrome. Screening tests included the Amsterdam criteria I/II, immunohistochemistry for loss of expression of one or more mismatch repair proteins and microsatellite instability testing.
|
|
|
|
|
|
|
